Opus Genetics, Inc. (IRD) Earnings Call Transcripts

Opus Genetics, Inc.'s Latest Earnings Call - June 16, 2026

Opus Genetics, Inc. held its earnings call for Q2 FY2026, focusing on its gene therapy pipeline for inherited retinal diseases (IRDs). The company did not report specific revenue or earnings figures, but emphasized its strategic advancements in clinical trials and pipeline development. Management highlighted that their current cash runway extends into 2029, supporting five clinical programs through multiple inflection points. No changes to financial guidance were mentioned, but the company outlined plans for several clinical trial initiations and data readouts over the next 12 to 18 months.

Reported metrics

Guidance from management

Opus Genetics did not provide specific financial guidance but indicated that its current cash runway will support clinical developments through 2029. The company plans several clinical trial initiations and data readouts over the next 12 to 18 months.

What management said

Thank you, Sally. We've had a few that have come in. Let me sort through these real quick. So for the first question for our guests, we should probably consider this sort of like a lightning round because we've got a number of questions. But I think for Dr. Fan, MacLaren and Vajzovic, let me read this out loud. So for IRDs that affect a relatively small number of patients, such as LCA 5, RDH 12 and MerTK, how difficu...

Great. Thank you. Next question, I think I'll direct to Dr. Sally Tucker. This one goes, in general, are you planning on testing these next 3 gene therapies in children or adolescents early on in clinical development? Or will data updates in 2027 likely be in adults?

What analysts pressed on

Analysts expressed concerns about patient identification and recruitment for rare IRDs, given the small patient populations and the need for genetic testing. Questions were also raised about the scalability of manufacturing processes for larger patient populations.

Main topics on the call

• Gene Therapy Pipeline Expansion — Opus Genetics is advancing a portfolio of 7 AAV gene therapy assets targeting inherited retinal diseases, leveraging a first-mover advantage and broad IP protection. CEO George Magrath stated, 'We are now in a position t...
• Clinical Trial Progress — The company is preparing to initiate clinical trials for RDH12, MERTK, and RO within the next 12 months, with expectations for up to four clinical trial readouts in 2027. 'We are entering a pivotal time for the company,'...
• LCA5 and BEST1 Programs — Opus Genetics reported significant improvements in visual acuity and sensitivity in both adult and pediatric cohorts for their LCA5 program. The BEST1 program has completed enrollment in Cohort 1 of the Phase I/II study.
• Patient Recruitment and Retention — Opus is implementing strategies to enhance patient recruitment and retention, including partnerships with patient advocacy groups and developing educational materials. 'We optimize patient engagement,' noted Chief Medica...

Read the full Opus Genetics, Inc. transcript (June 16, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 8 Opus Genetics, Inc. earnings call transcripts on record, spanning January 25, 2023 to June 16, 2026. Based on this history, Opus Genetics, Inc. reports semi-annually. The most recent call on file is dated June 16, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IRD

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

8

First call

January 25, 2023

Most recent

June 16, 2026

Reporting cadence

semi-annually